Entrada Therapeutics, Inc. (TRDA)
NASDAQ: TRDA · Real-Time Price · USD
4.845
+0.005 (0.10%)
Oct 29, 2026, 10:53 AM EDT - Market open
Entrada Therapeutics Employees
Entrada Therapeutics had 152 employees as of December 31, 2025. The number of employees decreased by 31 or 16.94% compared to the previous year. That makes Entrada Therapeutics the 28,728th largest employer in the world and 3,639th in the United States.
Employees
152
Change (1Y)
-31
Growth (1Y)
-16.94%
Revenue / Employee
$30,829
Profits / Employee
-$1,090,645
Market Cap
174.70M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 152 | -31 | -16.94% |
| Dec 31, 2024 | 183 | 24 | 15.09% |
| Sep 30, 2024 | 177 | 27 | 18.00% |
| Jun 30, 2024 | 168 | 37 | 28.24% |
| Mar 31, 2024 | 160 | 30 | 23.08% |
| Dec 31, 2023 | 159 | 29 | 22.31% |
| Sep 30, 2023 | 150 | 26 | 20.97% |
| Jun 30, 2023 | 131 | 9 | 7.38% |
| Mar 31, 2023 | 130 | 16 | 14.04% |
| Dec 31, 2022 | 130 | 16 | 14.04% |
| Sep 30, 2022 | 124 | 26 | 26.53% |
| Jun 30, 2022 | 122 | 44 | 56.41% |
| Mar 31, 2022 | 114 | 36 | 46.15% |
| Dec 31, 2021 | 114 | - | - |
| Sep 30, 2021 | 98 | - | - |
| Jun 30, 2021 | 78 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| ProQR Therapeutics | 187 |
| Adagene | 128 |
| Invivyd | 122 |
| Compugen | 75 |
| Precision BioSciences | 67 |
| Acumen Pharmaceuticals | 61 |
| Sionna Therapeutics | 59 |
| PepGen | 57 |
TRDA News
- 8 days ago - Entrada Therapeutics appoints Linea Aspesi as chief people officer - TheFly
- 8 days ago - Entrada Therapeutics Appoints Linea Aspesi as Chief People Officer - GlobeNewsWire
- 15 days ago - Entrada Therapeutics reports data from Cohort 1 of ELEVATE-45-201 clinical study - TheFly
- 15 days ago - Independent Safety Data Monitoring Committee Recommends Initiation of Cohort 3 at the Top Dose of 18 mg/kg in Entrada Therapeutics' ELEVATE-44-201 Study - GlobeNewsWire
- 15 days ago - Entrada Therapeutics Announces Positive Results from the First Cohort of Participants with Duchenne Muscular Dystrophy (DMD) in the Phase 1/2 ELEVATE-45-201 Study of ENTR-601-45 - GlobeNewsWire
- 7 weeks ago - Entrada Therapeutics Announces Recipients of Fourth Annual DREAMS Grant Program - GlobeNewsWire
- 7 weeks ago - Entrada Therapeutics Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference - Transcripts
- 1 month ago - Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire